Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CRHBP | P24387 | 1/20 | 0.33 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.33 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 4/20 | 0.32 |
| ▸ | F13A1 | P00488 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10150158 | 0.89 | HSP90AB1 (0.51) | HSP90AB1ABCG2POLBCRHBPCRHR2 | |
| SCHEMBL10150161 | 0.89 | HSP90AB1 (0.51) | HSP90AB1ABCG2POLBCRHBPCRHR2 | |
| SCHEMBL10150458 | 0.83 | HSP90AB1 (0.60) | HSP90AB1MAOBF13A1TGM2MAOA | |
| SCHEMBL10150175 | 0.83 | HSP90AB1 (0.41) | HSP90AB1ABCG2POLBCRHBPCRHR2 | |
| SCHEMBL10150181 | 0.83 | HSP90AB1 (0.41) | HSP90AB1ABCG2POLBCRHBPCRHR2 | |
| SCHEMBL10150021 | 0.77 | HSP90AB1 (0.70) | HSP90AB1CYP19A1F13A1TGM2MKNK2 | |
| SCHEMBL10150018 | 0.77 | HSP90AB1 (0.70) | HSP90AB1CYP19A1F13A1TGM2MKNK2 | |
| SCHEMBL10150138 | 0.77 | HSP90AB1 (0.48) | HSP90AB1ABCG2POLBCRHBPCRHR2 | |
| SCHEMBL19418453 | 0.74 | F13A1 (0.57) | HSP90AB1ABCG2CYP19A1F13A1TGM2 | |
| SCHEMBL10150026 | 0.74 | F13A1 (0.57) | HSP90AB1ABCG2CYP19A1F13A1TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450305-B2 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2013-05-28 | — | — | US | disclosed |
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-03-29 | — | — | US | disclosed |
| US-8067412-B2 | analogs of natural products radicicol and pochonins; (oxirane or cyclopropan) 2-benzoxacyclo(di)tetradecin derivatives; inhibition of kinase phosphorylation activity and heat shock proteins; anticarcinogenic, antiinflammatory agent; neurodegenerative diseases; antiallergen | UNIVERSITE DE STRASBOURG (FR) | 2011-11-29 | — | — | US | disclosed |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | UNIVERSITE DE STRASBOURG (FR) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077775-A1 | MACROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF KINASES AND HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885ABCG2 1124/4885POLB 1765/4885 |
| US-20080146545-A1 | Macrocyclic compounds useful as inhibitors of kinases and HSP90 | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AB1 1/4885ABCG2 1124/4885POLB 1765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.